SequelSEC

Vor Biopharma Inc. VOR

Biological Products, (No Diagnostic Substances) · CIK 0001817229 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$371.64M
Fiscal year ended 2025-12-31
Free cash flow
-$143.65M
Fiscal year ended 2025-12-31

Vor Biopharma Inc. (VOR) reported net income of -$695.98M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Vor Biopharma Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Vor Biopharma Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$371.64M-$121.18M-$126.04M-$93.42M-$69.02M-$43.37M
Net income-$695.98M-$116.91M-$117.86M-$92.09M-$68.90M-$43.34M
Research & development$321.53M$93.31M$94.32M$64.55M$47.53M$31.62M
Weighted-average diluted sharesshares 9.87Mshares 3.44Mshares 67.19Mshares 39.55Mshares 33.43MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-70.50$-34.03$-1.75$-2.33$-2.10Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$50.11M$27.88M$31.72M$28.87M$21.49M$11.75M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Vor Biopharma Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$396.49M$81.95M$31.36M$57.71M$119.80M$48.54M
Total assets$464.13M$142.89M$198.13M$299.37M$242.59M$75.91M
Current assets$458.10M$96.51M$140.80M$236.95M$214.40M$49.11M
Total liabilities$628.44M$46.23M$47.40M$48.76M$26.33M$27.64M
Current liabilities$25.17M$18.61M$15.57M$13.12M$10.15M$10.21M
Total equity incl. NCI-$164.31M$96.66M$150.72M$250.61M$216.26M-$59.06M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailable$107.34M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$5.13M$1.50M$815.00K$1.77M$1.54M$2.36M

Cash flow

Vor Biopharma Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$142.71M-$99.66M-$100.29M-$85.14M-$69.14M-$36.29M
Capital expenditures$941.00K$229.00K$1.07M$8.46M$3.89M$4.16M
Investing cash flow-$48.80M$96.86M$71.01M-$94.09M-$91.65M-$4.16M
Financing cash flow$503.81M$53.39M$2.94M$117.14M$232.91M$82.53M
Net change in cash$312.29M$50.59M-$26.35M-$62.10M$72.12M$42.07M
Stock-based compensation$18.91M$9.85M$13.36M$10.70M$4.32M$1.34M
Common dividends paid$0$0$0$0$0$0
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Vor Biopharma Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flow-$143.65M-$99.89M-$101.36M-$93.61M-$73.04M-$40.45M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio18.20x5.19x9.04x18.06x21.12x4.81x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VOR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.